Overview of the New Medicare-Endorsed Prescription Drug Discount Card Program The Intersection of Business Strategy and Public Policy The Health Strategies.

Slides:



Advertisements
Similar presentations
1 Medicare Part D: Cost Management Issues Jack Hoadley Research Professor Georgetown University Health Policy Institute Families USA Health Action 2005.
Advertisements

Medicare Prescription Drug Discount Card Ranjani Varadarajan PYPC 7810.
Challenges of Serving Low-income Medicare Beneficiaries: Impact of Cost Sharing Cindy Parks Thomas Brandeis University Schneider Institute for Health Policy.
The Medicare Drug Discount Card: A public-private partnership July 28, 2004 Grace-Marie Turner Galen Institute.
Supplementing PACE through Medicare Part D
Ideas for People Losing Illinois Cares Rx Benefits July 2011.
Medicare Part D and HIV/AIDS: What a Clinician May Want to Know Laura Cheever, M.D., ScM Deputy Director, Chief Medical Officer HIV/AIDS Bureau Health.
1 HOBBS STRAUS DEAN & WALKER, LLP WASHINGTON, DC | PORTLAND, OR | OKLAHOMA CITY, OK | SACRAMENTO, CA To Insure or Not to Insure Opportunities for Tribes.
MEDICARE: PAST, PRESENT AND F UTURE James G. Anderson, Ph.D. Department of Sociology & Anthropology.
© 2005 National Mental Health Association The Medicare Drug Benefit: What Is It and What Does it Mean for Mental Health? Get Educated, Get Enrolled An.
Medicare and the New Prescription Drug Benefit Presented by Tricia Neuman, Sc.D. Vice President and Director, Medicare Policy Project The Henry J. Kaiser.
Copyright © 2006 by The Segal Group, Inc., the parent of The Segal Company. All rights reserved. Options for Employers to Provide Retiree Coverage Post-
Medicare Prescription Drug Coverage. What’s Different About Prescription Drug Information? One size does not fit all, more than ever before Distinct messages.
Medicare Part D Overview of Options, Creditable Coverage, Required Notices, COB and Health Care Reform.
Medicare Modernization Act, Part D Prescription Drug Benefit Presentation for County Program Administrators September 1, 2005.
Joint Informational Hearing The Federal Medicare Prescription Drug Act: State Readiness, Implementation, and Consumer Issues Bonnie Burns, Training and.
Rutgers Center for State Health Policy June 28, 2005 Presentation to the Academy Health Kimberley Fox, Senior Policy Analyst Rutgers Center for State Health.
1 State Perspectives on Medicare Part D: Lessons from Pharmacy Plus Programs Cindy Parks Thomas Donald Shepard Christine E. Bishop Daniel M. Gilden Brandeis.
© 2005 National Mental Health Association The Medicare Drug Benefit: What Is It and What Does it Mean for Mental Health?
1 Medicare Prescription Drug Improvement and Modernization Act & Beneficiaries With Mental Illnesses Presentation to NAMI Convention June 19, 2005 Andrew.
Medicare Prescription Drug, Improvement, and Modernization Act of 2003 Roy Trudel, CMSO National Eligibility Workers Association 07/12/05.
What’s in the Mail? Overview of Medicare Prescription Drug Coverage Beneficiary Communications Employer Forum Conference Call October 13, 2005.
MEDICARE PART D Are We Ready? Are We Ready?. Medicare Part D Overview Medicare Part A and B covers individuals Age 65 and older Age 65 and older Those.
For Internal Use Only Not to be shared with customers Pharmaceutical Industry Patient Support Programs Ken McCormick National Director Strategic Accounts.
The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 Presented by Tricia Neuman, Sc.D. Vice President and Director, Medicare Policy.
Slide -1 Medicare Prescription Drug Benefit Denise S. Stanley, Pharm.D. Atlanta Regional Office Centers for Medicare & Medicaid Services March 17, 2006.
January National Medicare & You Training Program Amy Larrick, CMS NAACP April 27, 2006.
State Strategies: Expanding Prescription Drug Access Dee Mahan Families USA November 1, 2002.
The Pharmaceutical Industry’s Perspective on Medicare’s New Prescription Drug Benefit Marion McCourt AstraZeneca Vice President Government, Public Policy.
Medicare and Patient Assistance Sean M. Dougherty Senior Director Medicare Strategy & Patient Assistance Programs Government, Public Policy And Managed.
 The Impact of the Medicare Prescription Drug Legislation on Pharmaceutical Revenues Presented By: Jack Rodgers PricewaterhouseCoopers February 27,
The New Medicare Prescription Drug Benefit: An Overview Prepared by: Michelle Kitchman, M.H.S. Kaiser Family Foundation For the: California Senate Health.
0 Beneficiary Choices in Medicare Part D and Plan Features in 2006 Supported by PhRMA September 13, 2006.
Avalere Health LLC | The intersection of business strategy and public policy The Potential Impact of the New Prescription Drug Benefit on Medicare Beneficiaries.
Slide 1 Drug Pricing Considerations Medicare Prescription Drug, Improvement, and Modernization Act of 2003 ___________ Copyright 2005 Arnold & Porter July.
1 Medicare Part D: Cost Management Issues Jack Hoadley Research Professor Georgetown University Health Policy Institute National Academy of Social Insurance.
Draft Model Manufacturer Agreement Medicare Coverage Gap Discount Program Public Meeting June 1, 2010.
Ian D. Spatz Merck & Co., Inc. January 14, 2004 Ian D. Spatz Merck & Co., Inc. January 14, 2004 Overview of the New Medicare Prescription Drug Law.
K A I S E R C O M M I S S I O N O N Medicaid and the Uninsured Figure 0 Medicare Modernization Act of 2003: Implications for Low-Income People and State.
Medicare Reform: The Pharmacy Perspective John M. Coster, Ph.D., R.Ph. The National Medicare Prescription Drug Congress February 26, 2004.
Pharma Audioconference: PBM Regulation, Investigation, Prosecution and Compliance February 10, 2004 Stephanie W. Kanwit, Esq. Special Counsel Pharmaceutical.
“Reaching across Arizona to provide comprehensive quality health care for those in need” Our first care is your health care Arizona Health Care Cost Containment.
"Helping Seniors Make Smart Decisions about their Drug Coverage Options" Hal Prink, FHFMA, Medicare Patient Advocate, Senior’s Voice for Healthcare Rights.
Avalere Health LLC | The intersection of business strategy and public policy The Medicare Modernization Act: The Impact on States and Low-Income Beneficiaries.
Implications of the 2003 Medicare law for older adults and people with disabilities Translating “Legislative Sausage” into Understandable Choices Diane.
The Future of Medicare Advantage The Heritage Foundation September 10, 2008 James C. Capretta Fellow, Ethics and Public Policy Center
1 Cost Sharing for Low-Income Beneficiaries and Supplementing Part D Examples from Pharmacy Plus Medicaid Demonstration Programs Summit for State Health.
1 Medicare Reform: Implications for Pharmaceutical Manufacturers G. Lawrence Atkins, PhD Schering-Plough Corporation January 14, 2004.
Karissa A. Laur Director, Prescription Assistance Programs Coordinating Patient Assistance Programs with Medicare Part D: A Manufacturer’s Perspective.
1 State Options for Supplementing Medicare Part D Drug Coverage Invitational Summit on Medicare Part D Implementation Issues Jack Hoadley Georgetown University.
Third National Medicare Congress Marta Schroeder Divisional Vice President Public Health Policy & Strategy October 2006.
Medicare Prescription Drug Congress MMA and Medicaid Gale Arden Director, Disabled & Elderly Health Programs Group CMSO CMS October 2005.
National Conference of State Legislatures National Medicaid Congress June 5, 2006 State Pharmaceutical Assistance Programs, Medicaid & Part D: 2006 State.
Avalere Health LLC | The intersection of business strategy and public policy Enrollment in the Medicare Drug Benefit Medicare Congress Audioconference.
Managed Care Pharmacy Financials January 15, 2015.
Avalere Health LLC | The intersection of business strategy and public policy The Impact of Enrollment in the Medicare Prescription Drug Benefit on Premiums.
Overview of the New Medicare-Endorsed Prescription Drug Discount Card Program The Intersection of Business Strategy and Public Policy The Health Strategies.
State Responses to Medicare Part D Presented by: Kimberley Fox, Senior Policy Analyst, Institute for Health Policy Academy Health Annual Research Meeting.
1. 2 Y e s 3 Y e s The initial enrollment period for people with Medicare and some Medicaid is the same as for other enrollees. If these individuals.
Pharmacy Benefit Management (PBM) 101
Reimbursement Trends & Observations Presented by: John Aforismo B.Sc. Pharm., R.Ph Chairman & Founder RJ Health Systems International, LLC AMCP 21 st Annual.
Medicare Open Enrollment For Coverage in 2016 Starts October 15, 2015 Ends December 7, MEDICARE Medicare.gov.
Medicaid Influence in the Drug Market Dana Costea PhD student, Department of Economics, Lehigh University Franklin Carter Assistant Professor, Marketing.
Overview of the Medicare Drug Benefit Presented by Tricia Neuman, Sc.D. Vice President and Director, Medicare Policy Project The Henry J. Kaiser Family.
Rx carve Out Proposal Board Meeting April4, 2016.
Director, Pennsylvania PACE Program National Medicare Congress
Medicare Rx Legislation: Implications for PBMs
Will PBMs Participate in the New Medicare Prescription Drug Program
Presented by Tricia Neuman, Sc.D.
Medicare Reform: Implications for Pharmaceutical Manufacturers
Presentation transcript:

Overview of the New Medicare-Endorsed Prescription Drug Discount Card Program The Intersection of Business Strategy and Public Policy The Health Strategies Consultancy John Richardson National Pharma Audioconference January 28, 2004

The Health Strategies Consultancy 2 Outline of Talk Discount Card Implementation Schedule Target Population Eligibility and Enrollment – Transitional Assistance for Low-Income Enrollees Card Sponsor Requirements Drug Pricing Requirements Information Disclosure Requirements Formulary Requirements Concluding Thoughts

The Health Strategies Consultancy 3 Key Dates in Implementation of Medicare Drug Discount Card Program Dec. 8, 2003: MMA is signed into law Dec. 15: CMS publishes interim final rule for discount card program Dec : CMS holds pre-application conference for potential card sponsors and other interested parties Jan. 14, 2004: Deadline for public comment on interim final rule Jan. 30: Deadline for card sponsor applications to CMS End of March: Card sponsor contracts finalized April 1: Card sponsor information and outreach may begin April 30: CMS launches Discount Card Price Comparison Web site May 3: Card sponsors may begin enrollment June 1: Discount card program begins Nov Dec. 31: Enrollees may elect to switch cards for 2005 Jan. 1, 2006: Part D benefit starts; discount card program ends

The Health Strategies Consultancy 4 Target Population: Medicare Beneficiaries with No or Limited Rx Drug Coverage a. State-sponsored pharmaceutical assistance programs, VA, DoD, or M+C nonrisk contracts. Source: Congressional Budget Office based on data from the 1999 Medicare Current Beneficiary Survey (October 2002).

The Health Strategies Consultancy 5 Categories of Eligible Individuals Discount Card Eligibles Any beneficiary enrolled in Medicare Parts A or B No income limit Not enrolled in Medicaid or entitled to drug coverage under a Sec Medicaid waiver Transitional Assistance Eligibles Enrolled in Parts A or B No Rx coverage under: – Group health plan or individual health insurance policy – VA or DoD – FEHBP Income less than 135% FPL* – Eligibility will be self-declared – CMS authorized to verify eligibility *135% of FPL in 2004 is $12,120 for a one-person household and $16,360 for a two-person household.

The Health Strategies Consultancy 6 Enrollment Enrollment in discount card program is voluntary – CMS estimates 7.3 million enrollees in 2004 and 2005 – 4.7 million enrollees expected to be TA eligible Enrollment allowed in only one Medicare-endorsed card at a time – There will be one “coordinated election period” to switch cards – Enrollees may continue to use other, non-endorsed cards Cards may charge annual enrollment fee of up to $30 – CMS will pay enrollment fee directly to card sponsors for TA eligible beneficiaries – States may pay for enrollees with incomes above 135% of FPL, but with State-only funds

The Health Strategies Consultancy 7 Transitional Assistance for Low- Income Enrollees $600 Federal subsidy provided in 2004 and 2005 to card enrollees with incomes below 135% FPL – Unused funds from 2004 may rollover to 2005 – Amount in 2005 will be pro-rated if mid-year enrollment CMS will pay annual enrollment fee (if any) directly to card sponsors Beneficiaries required to make copayments, based on percent of negotiated prices – 5% co-pay if income is below 100% FPL* – 10% co-pay if income is between 100% and 135% FPL* – States may “wrap around” to cover co-pays, but expenditures not eligible for Federal Medicaid matching funds *100% of FPL in 2004 is $8,980 for one-person household and $12,120 for two-person household. 135% of FPL is $12,120 and $16,360, respectively.

The Health Strategies Consultancy 8 Card Sponsor Requirements CMS will not limit the number of discount card programs operating in a State Minimum application requirements for card sponsors: – At least three (3) years of experience in pharmacy benefit management (as defined specifically in the regulation) – Current operation of a pharmacy benefit program, drug discount card program, or low-income drug assistance program that serves at least 1 million covered lives Card sponsors must have pharmacy network, other than mail- order, that meets TRICARE 2003 pharmacy access standards – Pharmacy network may be supplemented by mail-order pharmacies Card sponsors must be able to administer “transitional assistance” funds, including roll-over funds MedicareAdvantage plans that sponsor a discount card have exclusive enrollment rights to their plan members

The Health Strategies Consultancy 9 Drug Pricing Requirements Card sponsor must guarantee enrollees access to “negotiated price” – Negotiated price is “discounted price, including any dispensing fee, which takes into account negotiated price concessions, such as discounts, direct or indirect subsidies, rebates, or direct or indirect remunerations.” (42 CFR ) Card sponsors must pass a “share” of negotiated price concessions to enrollees through negotiated prices Negotiated prices will not be included in Medicaid best price calculations CMS estimates per prescription savings of 10%-15% off retail (cash) price – Rule does not require card sponsors to guarantee level of savings

The Health Strategies Consultancy 10 Price Information Disclosure Requirements Card sponsors must report the following to CMS: – Negotiated prices for every covered drug at NDC level – Aggregate savings obtained from manufacturers and pharmacies – Aggregate savings shared with discount card enrollees – Dispensing fees by pharmacy – Notice and rationale for increases in negotiated prices due to reasons other than AWP changes Confidentiality of pricing data as under Medicaid Pharmacies must inform enrollees at point-of-sale of any difference between price of prescribed drug and price of lowest priced available generic alternative CMS will establish a price comparison Web site and issue printed comparison guides – Card sponsors may update weekly

The Health Strategies Consultancy 11 Formulary Requirements Authorizing law does not specifically mention formularies, but… Sum of regulatory requirements on card sponsors suggests interpretation that all card sponsors must use a formulary CMS has defined a list of 209 therapeutic categories – CMS states that this is a “minimum requirement” – Card sponsors may add more categories or further differentiate categories through P&T committees Formularies must include one brand drug in each of the 209 therapeutic categories – For drugs that can be classified into more than one category, a drug can be used only once to satisfy this requirement Formularies must include one generic drug in 115 (55%) of the 209 categories – 115 categories represent about 95 percent of the categories that include a Class A generic drug, according to CMS and the FDA Orange Book Conclusion: Card sponsors will have to negotiate many manufacturer contracts very quickly to meet minimum formulary requirement

The Health Strategies Consultancy 12 Concluding Thoughts Nature of drug price disclosures—how well will beneficiaries understand and process drug pricing information (e.g., savings compared to what?) Will CMS-mandated “therapeutic categories” produce manufacturer rebates and thus added value for beneficiaries? Discount card program is “first date” between CMS and pharmaceutical/PBM industry – Strong interest thus far from potential card sponsors – Opportunity in marketing of card and establishing brand visibility – CMS balancing regulatory oversight and incredibly fast “go-live” imperative, while also learning about very complex industry – Both partners building relationship needed for success of Part D